Featured Research

from universities, journals, and other organizations

Combination treatments benefits melanoma patient

Date:
March 7, 2012
Source:
Ludwig Institute for Cancer Research
Summary:
Scientists have shown that combining targeted radiation therapy with immunotherapy (ipilimumab), fostered a strong immune response and a favorable clinical outcome in a patient with melanoma, the most dangerous form of skin cancer. The size of both the tumor that was treated with radiation and distant tumors in the patient were reduced.

Research published March 8 in the New England Journal of Medicine by scientists at the Ludwig Institute for Cancer Research (LICR) and Memorial Sloan-Kettering Cancer Center (MSKCC) showed that combining targeted radiation therapy with immunotherapy (ipilimumab), fostered a strong immune response and a favorable clinical outcome in a patient with melanoma, the most dangerous form of skin cancer. The size of both the tumor that was treated with radiation and distant tumors in the patient were reduced. This study is a rare example of a documented case of an immune response, known as the abscopal effect, in cancer treatment.

The research team led by Jedd Wolchok, M.D., Ph.D., Assistant Member of LICR, Associate Attending Physician and Director of Immunotherapy Clinical Trials at MSKCC and Director of the CRI/LICR Cancer Vaccine Collaborative, took their findings a step further by investigating how the immune system may have played a role in the enhanced tumor regression. "We evaluated whether there were changes in the blood, which would help us to understand why the combined ipilimumab/radiation treatment improved the patient's response," said Dr. Wolchok.

What the team found was that the patient had a pre-existing immune response to an antigen known as NY-ESO-1, which was discovered by LICR researchers more than a decade ago. Select cancer patients produce antibodies and develop T-cell responses to NY-ESO-1, and research has shown that cancer patients who have pre-existing immunity to NY-ESO-1 are more likely to respond to the immunotherapy treatment, ipilimumab, than those who do not.

"The use of radiation therapy modulated the patient's immune system, resulting in an increased antibody response to one portion of the NY-ESO-1 protein, as well as increased antibody responses to other antigens," said Dr. Wolchok. "In addition, the radiation decreased the level of a population of suppressive cells, allowing the immune system to function more robustly and leading to better recognition and control of the disease."

Together, these data showed that radiation given locally can impact the immune system globally. Today, the patient continues to have a durable regression of melanoma both within and outside of the irradiated field. In the study, researchers followed the patient for seven years from her initial diagnosis of melanoma in 2004 through a series of treatments and eventual disease regression in April 2011 after a combination treatment of radiation and immunotherapy.

"The immune system differs in each of us. In studying one person's response, we were able to carefully investigate the clinical findings with in-depth laboratory studies, which suggested that a change in the immune system was vital to the successful results," added Dr. Wolchok.

The patient's dramatic systemic response following targeted radiation therapy in combination with immunotherapy has spurred interest in pursuing clinical trials to further validate this approach for prostate cancer and melanoma.

The team dedicated the study to the memory of Dr. Lloyd Old, a visionary leader in the field of tumor immunology. Dr. Old was Scientific Director of LICR from 1988 -- 2005 and Director of the New York Branch of LICR where much of the work in the paper was undertaken. Funding for this research was provided by LICR, as well as by the American Cancer Society, the Cancer Research Institute, the Commonwealth Foundation for Cancer Research, the Lita Annenberg Hazen Foundation, the Melanoma Research Alliance, MSKCC, the National Institutes of Health and Swim Across America.


Story Source:

The above story is based on materials provided by Ludwig Institute for Cancer Research. Note: Materials may be edited for content and length.


Journal Reference:

  1. Michael A. Postow, Margaret K. Callahan, Christopher A. Barker, Yoshiya Yamada, Jianda Yuan, Shigehisa Kitano, Zhenyu Mu, Teresa Rasalan, Matthew Adamow, Erika Ritter, Christine Sedrak, Achim A. Jungbluth, Ramon Chua, Arvin S. Yang, Ruth-Ann Roman, Samuel Rosner, Brenna Benson, James P. Allison, Alexander M. Lesokhin, Sacha Gnjatic, Jedd D. Wolchok. Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma. New England Journal of Medicine, 2012; 366 (10): 925 DOI: 10.1056/NEJMoa1112824

Cite This Page:

Ludwig Institute for Cancer Research. "Combination treatments benefits melanoma patient." ScienceDaily. ScienceDaily, 7 March 2012. <www.sciencedaily.com/releases/2012/03/120307185101.htm>.
Ludwig Institute for Cancer Research. (2012, March 7). Combination treatments benefits melanoma patient. ScienceDaily. Retrieved October 22, 2014 from www.sciencedaily.com/releases/2012/03/120307185101.htm
Ludwig Institute for Cancer Research. "Combination treatments benefits melanoma patient." ScienceDaily. www.sciencedaily.com/releases/2012/03/120307185101.htm (accessed October 22, 2014).

Share This



More Health & Medicine News

Wednesday, October 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Working Mother (Oct. 22, 2014) Is your child ready? Video provided by Working Mother
Powered by NewsLook.com
U.S. Issues Ebola Travel Restrictions, Are Visa Bans Next?

U.S. Issues Ebola Travel Restrictions, Are Visa Bans Next?

Newsy (Oct. 22, 2014) Now that the U.S. is restricting travel from West Africa, some are dropping questions about a travel ban and instead asking about visa bans. Video provided by Newsy
Powered by NewsLook.com
US to Track Everyone Coming from Ebola Nations

US to Track Everyone Coming from Ebola Nations

AP (Oct. 22, 2014) Stepping up their vigilance against Ebola, federal authorities said Wednesday that everyone traveling into the US from Ebola-stricken nations will be monitored for symptoms for 21 days. (Oct. 22) Video provided by AP
Powered by NewsLook.com
Doctors Help Paralysed Man Walk Again, Patient in Disbelief

Doctors Help Paralysed Man Walk Again, Patient in Disbelief

AFP (Oct. 22, 2014) Polish doctors describe how they helped a paralysed man walk again, with the patient in disbelief at the return of sensation to his legs. Duration: 1:04 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

More Coverage


Rare Medical Phenomenon of Systemic Tumor Disappearance Following Local Radiation Treatment Reported in a Patient With Metastatic Melanoma

Mar. 7, 2012 A rarely seen phenomenon in cancer patients — in which focused radiation to the site of one tumor is associated with the disappearance of metastatic tumors all over the body — has been reported ... read more

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins